Covered recipient · General Payments record
ANNEYD M AVALOS-PENA
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$408.85
17 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $408.85 | 17 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk Inc | $145.45 | 2 |
| Medtronic, Inc. | $81.01 | 5 |
| Abbott Laboratories | $61.87 | 3 |
| Lilly USA, LLC | $19.79 | 1 |
| Amgen Inc. | $18.59 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.56 | 1 |
| Amneal Pharmaceuticals LLC | $17.08 | 1 |
| PFIZER INC. | $16.71 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $15.67 | 1 |
| Esperion Therapeutics, Inc. | $15.12 | 1 |
Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ANNEYD M AVALOS-PENA
NPI 1962863266 · CMS profile ID 1840767
Allopathic & Osteopathic Physicians / Internal Medicine
DORAL, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1962863266?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ANNEYD M AVALOS-PENA, NPI 1962863266, CMS profile ID 1840767. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962863266?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). ANNEYD M AVALOS-PENA, NPI 1962863266, CMS profile ID 1840767. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962863266?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- ANNEYD M AVALOS-PENA, NPI 1962863266, CMS profile ID 1840767, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1962863266?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
17 matching records · $408.85 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–17 of 17.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $24.86 | 09/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1018551363 | CMS |
| Abbott Laboratories | $22.81 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1018533375 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.56 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057415003 | CMS |
| Medtronic, Inc. | $17.58 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026449509 | CMS |
| Medtronic, Inc. | $17.65 | 03/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026449507 | CMS |
| Amneal Pharmaceuticals LLC | $17.08 | 03/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053475279 | CMS |
| Abbott Laboratories | $14.20 | 03/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1018543755 | CMS |
| Medtronic, Inc. | $13.61 | 03/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026449505 | CMS |
| Novo Nordisk Inc | $23.58 | 03/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000951143 | CMS |
| PFIZER INC. | $16.71 | 02/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049490359 | CMS |
| Novo Nordisk Inc | $121.87 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000945163 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $15.67 | 02/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1038224825 | CMS |
| Medtronic, Inc. | $14.25 | 02/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026449503 | CMS |
| Medtronic, Inc. | $17.92 | 01/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026449501 | CMS |
| Lilly USA, LLC | $19.79 | 01/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031264381 | CMS |
| Esperion Therapeutics, Inc. | $15.12 | 01/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050732291 | CMS |
| Amgen Inc. | $18.59 | 01/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020536445 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2021, 2022, 2023, 2024
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,233,378.84 | 41 |
| PY2024 | Principal investigator | $194,841.92 | 17 |
| PY2023 | Principal investigator | $8,611.56 | 4 |
| PY2022 | Principal investigator | $18,460.00 | 5 |
| PY2021 | Principal investigator | $41,000.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
41 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,734.50 | 12/09/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603466 |
| Principal investigator 1 | Mylan Pharmaceuticals Inc. | $24,385.35 | 12/09/2025 | Non-covered Recipient Entity Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC | MR-139A-01-OMZ-1001 | No dispute reported | 06/30/2026 | 1238531884 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 11/21/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603545 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 11/21/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603553 |
| Principal investigator 1 | Mylan Pharmaceuticals Inc. | $102,227.25 | 11/21/2025 | Non-covered Recipient Entity Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC | FFUV-IHP-1003 | No dispute reported | 06/30/2026 | 1238531814 |
| Principal investigator 1 | Mylan Pharmaceuticals Inc. | $85,189.38 | 11/14/2025 | Non-covered Recipient Entity Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC | FFUV-IHP-1003 | No dispute reported | 06/30/2026 | 1238531812 |
| Principal investigator 1 | Genentech, Inc. | $213.87 | 11/07/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603549 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $159,021.40 | 11/07/2025 | Non-covered Recipient Entity CLINICAL PHARMACOLOGY OF MIAMI | A Phase 1, open-label study to investigate the pharmacokinetics and safety of remibrutinib (LOU064) in participants with severe renal impairment compared to matched healthy participants with normal renal function | No dispute reported | 06/30/2026 | 1190306253 |
| Principal investigator 1 | Mylan Pharmaceuticals Inc. | $134,826.51 | 10/28/2025 | Non-covered Recipient Entity Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC | BUPI-ISL-1004 | No dispute reported | 06/30/2026 | 1238531838 |
| Principal investigator 1 | Genentech, Inc. | $100.00 | 10/27/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603536 |
| Principal investigator 1 | Genentech, Inc. | $16,334.64 | 10/27/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603540 |
| Principal investigator 1 | ModernaTX, Inc. | $1,375.00 | 10/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992362 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 10/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992368 |
| Principal investigator 1 | ModernaTX, Inc. | $2,254.50 | 10/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992370 |
| Principal investigator 1 | ModernaTX, Inc. | $769.50 | 10/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992372 |
| Principal investigator 1 | ModernaTX, Inc. | $376.65 | 10/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992374 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 10/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992378 |
| Principal investigator 1 | ModernaTX, Inc. | $900.00 | 10/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992380 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 10/24/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992382 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 09/17/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992364 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 09/17/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992366 |
| Principal investigator 1 | ModernaTX, Inc. | $1,750.00 | 09/17/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992376 |
| Principal investigator 1 | AstraZeneca UK Limited | $134,943.50 | 08/29/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY, LLC | A SingleDose NonRandomised OpenLabel ParallelGroup Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics Safety and Tolerability of Opemalirsen AZD2373 | No dispute reported | 06/30/2026 | 1185548201 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,057.50 | 08/21/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity | No dispute reported | 06/30/2026 | 1184303243 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $90.00 | 07/30/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603417 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $9,958.50 | 07/30/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603422 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,138.00 | 07/30/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603426 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $812.50 | 07/30/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603431 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,423.00 | 07/14/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603449 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,311.50 | 07/07/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603457 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $21,242.50 | 07/01/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603435 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,195.50 | 07/01/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603440 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,120.00 | 07/01/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603443 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $7,875.00 | 07/01/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603453 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $7,097.00 | 07/01/2025 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE1 OPEN-LABEL STUDY TO ASSESS THE EFFECT OF RENAL IMPAIRMENT IN SUBJECTS TREATED WITH CT388 | No dispute reported | 06/30/2026 | 1211603462 |
| Principal investigator 1 | Mylan Pharmaceuticals Inc. | $134,372.70 | 05/13/2025 | Non-covered Recipient Entity Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC | MR-139A-01-OMZ-1001 | No dispute reported | 06/30/2026 | 1238531888 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 05/08/2025 | Non-covered Recipient Entity ELIAS RESEARCH ASSOCIATES LLC | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | No dispute reported | 06/30/2026 | 1252992384 |
| Principal investigator 1 | Mylan Pharmaceuticals Inc. | $104,662.95 | 05/06/2025 | Non-covered Recipient Entity Clinical Pharmacology of Miami, LLC, a subsidiary of ERG Holding Company, LLC | MR-139A-01-OMZ-1001 | No dispute reported | 06/30/2026 | 1238531886 |
| Principal investigator 1 | Amgen Inc. | $33,273.00 | 04/24/2025 | Non-covered Recipient Entity D AND H NATIONAL RESEARCH CENTERS INC | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246640575 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $203,621.89 | 02/26/2025 | Non-covered Recipient Entity Erg Holding Company Llc | A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis | No dispute reported | 06/30/2026 | 1235997463 |
| Principal investigator 1 | Amgen Inc. | $12,225.25 | 01/21/2025 | Non-covered Recipient Entity D AND H DORAL RESEARCH CENTERS | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246640571 |